AlgoTx unveils plans for Phase II trial for rare chronic condition
Pharmaceutical Technology
MARCH 29, 2023
AlgoTx remains on track to start enrolling subjects of a Phase II study of its compound ATX01 for the rare condition erythromelalgia in Q2 2023, says CEO Stéphane Thiroloix. In June 2020, the FDA gave ATX01 an orphan drug designation in erythromelalgia. Please check your email to download the Report.
Let's personalize your content